NVA Funds First Vulvodynia Treatment Registry

The NVA awarded Drs. Georgine Lamvu, Denniz Zolnoun and Lori Boardman grants to develop and implement the first-ever Vulvodynia Treatment Registry. Launching in fall 2009, this multi-site registry will study the efficacy of multiple treatments, including, but are not limited to, topical medications (e.g., lidocaine, gabapentin); oral "pain-blocking" medications (e.g., tricyclic antidepressants, anticonvulsants and muscle relaxants); physical therapy; and surgery. Women receiving medical care at the University of North Carolina, University of Central Florida, and Florida Hospital will be eligible to participate in the Registry.

Upon enrollment, participants will undergo a thorough medical evaluation and tests to assess vestibular skin and pelvic muscle sensitivity. They will also complete several questionnaires on pain, sexual function and quality of life. All tests and questionnaires will be administered multiple times during a two-year period to assess the long-term benefit of treatment. In addition to determining which treatments are effective, we hope that data collected through the Registry will clarify why only some women benefit from a particular treatment and identify factors that can predict treatment success in different subgroups of vulvodynia patients. Additionally, the Registry's findings will help guide the development of controlled treatment trials, which have been lacking in the vulvodynia field. Read more about the registry at www.nva.org target="_blank".

Posted July 3, 2009